A Phase 3 interventional study of OCS-01 and Vehicle in Inflammation Eye Pain and Postoperative Cataract, sponsored by Oculis. Terminated at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Oculis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.
Among the 456 studies in Cataract with a site in United States, this one is the 143rd largest by enrollment of the 322 interventional ones that give a count, is one of 28 that started in 2023, is one of 57 in phase 3, and was the 377th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eric Rosenberg · Sites in United States
Ages 18–90
The Eye Institute of West Florida · Sites in United States
Ages 40+
Gainesville Eye Associates · Sites in United States
Ages 18+
Laser Defined Vision · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
456 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 59 · Phase 4 86
First in 1987; this study’s year is marked. 28 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 100 across the 322 interventional studies, 61 across the 128 observational. Of the 365 that completed or were terminated, 177 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
239 of 456 have an industry lead sponsor. The 10 most frequent:
Oculis is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Oculis has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
21 of the studies in Cataract with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07898917Gainesville Eye AssociatesPureSee/Odyssey Mix-and-Match IOL | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07260695Center For SightOdyssey Evaluation in Post LASIK Patients | 2026-12-18 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT07715591University of California, Los AngelesRandomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 456 studies in Cataract with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 drop of OCS-01 (Dexamethasone ophthalmic suspension, 1.5% \[15 mg/mL\]) in the study eye once daily (QD) for 14 days, beginning 1-day post-surgery in the study eye.
Drug: OCS-01
1 drop of vehicle in the study eye QD for 14 days, beginning 1-day post-surgery in the study eye.
Drug: Vehicle
Dexamethasone ophthalmic suspension, 1.5%
Vehicle
Absence of Anterior Chamber Cells at Visit 6.
Time frame: Day 15.
Absence of Ocular Pain at Visit 4.
Time frame: Day 4.
Absence of Anterior Chamber Cells at Visits 4 and 5.
Time frame: Days 4 and 8.
Absence of Ocular Pain at Visits 3, 5, and 6.
Time frame: Days 2, 8, and 15.
Absence of Flare at Visits 4, 5, and 6.
Time frame: Days 4, 8, and 15.
Absence of Both Anterior Chamber Cells and Flare at Visits 4, 5, and 6.
Time frame: Days 4, 8, and 15.
Use of Rescue Medication on or Prior to Each Visit.
Time frame: Days 1, 2, 4, 8, 15, and 22.
Use of Rescue Medication Overall.
Time frame: From first dose until Day 22.
| Milestone | OCS-01 | Vehicle |
|---|---|---|
| Started | 67 | 50 |
| Completed | 67 | 50 |
| Not completed | 0 | 0 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Absence of Anterior Chamber Cells at Visit 6. | 40 | 15 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Absence of Ocular Pain at Visit 4. | 51 | 26 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Absence of Anterior Chamber Cells at Visit 4 | 8 | 2 |
| Absence of Anterior Chamber Cells at Visit 5 | 17 | 4 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Absence of Ocular Pain at Visit 3 | 43 | 23 |
| Absence of Ocular Pain at Visit 5 | 59 | 32 |
| Absence of Ocular Pain at Visit 6 | 67 | 41 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Absence of Flare at Visit 4 | 47 | 31 |
| Absence of Flare at Visit 5 | 53 | 36 |
| Absence of Flare at Visit 6 | 66 | 44 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Absence of Both Anterior Chamber Cells and Flare at Visit 4 | 8 | 1 |
| Absence of Both Anterior Chamber Cells and Flare at Visit 5 | 17 | 4 |
| Absence of Both Anterior Chamber Cells and Flare at Visit 6 | 40 | 15 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Use of Rescue Medication at Visit 2 | 0 | 0 |
| Use of Rescue Medication at Visit 3 | 0 | 1 |
| Use of Rescue Medication at Visit 4 | 1 | 2 |
| Use of Rescue Medication at Visit 5 | 6 | 20 |
| Use of Rescue Medication at Visit 6 | 11 | 29 |
| Use of Rescue Medication at Visit 7 | 16 | 30 |
| Participants | OCS-01 | Vehicle |
|---|---|---|
| Use of Rescue Medication Overall. | 16 | 30 |
Collected over From first dose until Day 22.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OCS-01 | 0/67 (0%) | 0/67 (0%) | 6/67 (9%) |
| Vehicle | 0/50 (0%) | 0/50 (0%) | 5/50 (10%) |
| Event | OCS-01 | Vehicle |
|---|---|---|
| Eye inflammationEye disorders | 6/67 | 5/50 |
The safety population included all randomized participants who received at least 1 dose of study medication.
| Age, Continuous(years) | OCS-01 | Vehicle | Total |
|---|---|---|---|
| Mean | 67.9 ± 7.60 | 67.0 ± 7.93 | 67.5 ± 7.72 |
| Sex: Female, Male(Participants) | OCS-01 | Vehicle | Total |
|---|---|---|---|
| Female | 41 | 27 | 68 |
| Male | 26 | 23 | 49 |
| Ethnicity (NIH/OMB)(Participants) | OCS-01 | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 16 | 41 |
| Not Hispanic or Latino | 42 | 34 | 76 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | OCS-01 | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 9 | 20 |
| White | 53 | 40 | 93 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2023 to primary completion in May 2024, 4 months.
Results were first posted in Jul 2026, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: OCS-01
Oculis